AMLX Amylyx Pharmaceuticals Inc
Company Analysis
Latest News
🔴 Amylyx Pharmaceuticals falls 4.2% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Amylyx Target Hits $57 at Guggenheim, Citing Avexitide Trial Success
Guggenheim raised its price target for Amylyx Pharmaceuticals to $57. The firm updated its valuation model following successful Phase 3 LUCIDITY trial results...
🔴 Amylyx Pharmaceuticals is trading 4.46% down today after upsized $575 million public offering
Amylyx Pharmaceuticals is trading 4.46% down at $35.79 after completing an upsized public offering that raised approximately $575.2 million before expenses. -...
Deutsche Bank Takes New Position in Amylyx as Institutional Interest Surges Following Positive Trial Data
Deutsche Bank disclosed a new stake in Amylyx Pharmaceuticals, having purchased 557,937 shares in the second quarter, a position valued at over $10 million....
Amylyx Pharmaceuticals Closes $500M Offering, Funding Avexitide Launch
Amylyx Pharmaceuticals closed its upsized public offering of 14,090,000 common stock shares. The company priced the offering at $35.50 per share. Gross...
Announces Public Stock Offering to Raise ~$472 Million in Net Proceeds
Amylyx Pharmaceuticals, Inc. entered into an underwriting agreement for a public offering of 14,090,000 shares of its common stock at a public price of $35.50...
🟢 Amylyx Pharmaceuticals up 4% today after positive Phase 3 LUCIDITY results and expanded $500M equity offering
Amylyx Pharmaceuticals is trading 4.03% up today at $40.16. - This follows continued strong investor response to positive Phase 3 LUCIDITY results for...
Amylyx Announces Positive Phase 3 Trial Results for Avexitide in Hypoglycemia
Amylyx Pharmaceuticals announced positive topline results from its Phase 3 LUCIDITY clinical trial for avexitide, an investigational treatment for...
Amylyx Reports Positive Phase 3 LUCIDITY Trial Results for Avexitide
Amylyx Pharmaceuticals announced positive topline results from its Phase 3 LUCIDITY clinical trial for avexitide, an investigational treatment for...
Amylyx Drug Hits Phase 3 Goal, Cutting Severe Hypoglycemia by 55%
Amylyx Pharmaceuticals announced that its experimental drug, avexitide, met the primary endpoint of the Phase 3 LUCIDITY trial. The study focused on...